Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacek Capala

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Technology in Cancer Research & Treatment|September 5, 2013
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probeYasaman Ardeshirpour, Moinuddin Hassan, Rafal Zielinski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial ResourcesJacek Capala, Stephen A Graves, Aaron Scott, et al.
Chembiochem : a European Journal of Chemical Biology|January 7, 2010
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imagingIlya Lyakhov, Rafal Zielinski, Monika Kuban, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the UnknownsRichard L Wahl, George Sgouros, Amir Iravani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 20, 2011
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes)Brandon Smith, Ilya Lyakhov, Kristin Loomis, et al.
Frontiers in Oncology|March 22, 2021
Radiopharmaceutical Validation for Clinical UseCharles A Kunos, Rodney Howells, Aman Chauhan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2012
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor modelGabriela Kramer-Marek, Merel Gijsen, Dale O Kiesewetter, et al.
Molecular Imaging|August 23, 2007
Fluorescence lifetime imaging system for in vivo studiesMoinuddin Hassan, Jason Riley, Victor Chernomordik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imagingSang Bong Lee, Moinuddin Hassan, Robert Fisher, et al.
Translational Oncology|March 8, 2016
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and RecommendationsHelen B Stone, Eric J Bernhard, C Norman Coleman, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Technology in Cancer Research & Treatment|September 5, 2013
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probeYasaman Ardeshirpour, Moinuddin Hassan, Rafal Zielinski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial ResourcesJacek Capala, Stephen A Graves, Aaron Scott, et al.
Chembiochem : a European Journal of Chemical Biology|January 7, 2010
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imagingIlya Lyakhov, Rafal Zielinski, Monika Kuban, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the UnknownsRichard L Wahl, George Sgouros, Amir Iravani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 20, 2011
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes)Brandon Smith, Ilya Lyakhov, Kristin Loomis, et al.
Frontiers in Oncology|March 22, 2021
Radiopharmaceutical Validation for Clinical UseCharles A Kunos, Rodney Howells, Aman Chauhan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2012
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor modelGabriela Kramer-Marek, Merel Gijsen, Dale O Kiesewetter, et al.
Molecular Imaging|August 23, 2007
Fluorescence lifetime imaging system for in vivo studiesMoinuddin Hassan, Jason Riley, Victor Chernomordik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imagingSang Bong Lee, Moinuddin Hassan, Robert Fisher, et al.
Translational Oncology|March 8, 2016
Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and RecommendationsHelen B Stone, Eric J Bernhard, C Norman Coleman, et al.
Pageof 10